Related Experiment Video

Updated: Apr 28, 2026

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:21

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

119

Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of

Rossano Lattanzio1, Rossana La Sorda1, Francesco Facciolo2

  • 1Center of Excellence for Research on Ageing, "University G. D'Annunzio" Foundation, Chieti, Italy.

Lung Cancer (Amsterdam, Netherlands)
|June 9, 2014
PubMed
Abstract

Insights

High-risk thymic epithelial tumors (TET) show increased expression of vascular endothelial growth factor (VEGF) family members and their receptors. These findings suggest anti-angiogenic therapies could be effective for advanced TET.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Tumor angiogenesis is crucial for tumor growth and a therapeutic target.
  • Angiogenesis inhibitors targeting VEGF are FDA-approved.
  • Targeted therapies for rare thymic epithelial tumors (TET) are limited.

Purpose of the Study:

  • To investigate angiogenesis-related biomarkers in TET.
  • To identify potential therapeutic targets for TET.

Main Methods:

  • Immunohistochemistry was used to analyze 200 TET samples.
  • Expression of VEGFA, VEGFC, VEGFD, VEGFR1, VEGFR2, VEGFR3, and PDGFRβ was assessed.
  • Tissue Micro Arrays (TMA) were utilized.

Main Results:

  • High-risk TET exhibited higher expression of VEGFA, VEGFC, VEGFD, VEGFR1, VEGFR2, and VEGFR3 compared to low-risk tumors.
  • No significant difference in PDGFRβ expression was observed.
  • P-values < 0.05 indicate statistical significance for observed differences.

Conclusions:

  • Multiple paracrine and/or autocrine loops involving angiogenesis are present in TET, especially high-risk types.
  • These loops contribute to TET growth and progression.
  • Anti-angiogenic agents warrant consideration for advanced TET treatment.
Keywords:
BiomarkersThymic epithelial tumorsThymomaTissue Micro ArrayVascular endothelial growth factorVascular endothelial growth factor receptor

More Related Videos

Isolation and Culture Expansion of Tumor-specific Endothelial Cells10:15

Isolation and Culture Expansion of Tumor-specific Endothelial Cells

Published on: October 14, 2015

10.6K
A Matrigel-Based Tube Formation Assay to Assess the Vasculogenic Activity of Tumor Cells04:00

A Matrigel-Based Tube Formation Assay to Assess the Vasculogenic Activity of Tumor Cells

Published on: September 7, 2011

66.0K

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.4K